We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Booster shot

11 September 2017 By Neil Unmack

Installing former Lundbeck boss Kare Schultz as CEO has given the Israeli drugmaker’s shares a shot in the arm. The new boss now needs to cut costs, and manage the group’s $35 bln debt pile. That’s hard given Teva’s challenges, and a tough market for generic drugs.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)